302 related articles for article (PubMed ID: 9287333)
1. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site.
Arteaga CL; Ramsey TT; Shawver LK; Guyer CA
J Biol Chem; 1997 Sep; 272(37):23247-54. PubMed ID: 9287333
[TBL] [Abstract][Full Text] [Related]
2. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
3. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
Lichtner RB; Menrad A; Sommer A; Klar U; Schneider MR
Cancer Res; 2001 Aug; 61(15):5790-5. PubMed ID: 11479217
[TBL] [Abstract][Full Text] [Related]
4. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity.
Busse D; Doughty RS; Ramsey TT; Russell WE; Price JO; Flanagan WM; Shawver LK; Arteaga CL
J Biol Chem; 2000 Mar; 275(10):6987-95. PubMed ID: 10702262
[TBL] [Abstract][Full Text] [Related]
5. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation.
Jain A; Penuel E; Mink S; Schmidt J; Hodge A; Favero K; Tindell C; Agus DB
Cancer Res; 2010 Mar; 70(5):1989-99. PubMed ID: 20160029
[TBL] [Abstract][Full Text] [Related]
6. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.
Xie H; Lin L; Tong L; Jiang Y; Zheng M; Chen Z; Jiang X; Zhang X; Ren X; Qu W; Yang Y; Wan H; Chen Y; Zuo J; Jiang H; Geng M; Ding J
PLoS One; 2011; 6(7):e21487. PubMed ID: 21789172
[TBL] [Abstract][Full Text] [Related]
7. Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolines.
Bridges AJ; Cody DR; Zhou H; McMichael A; Fry DW
Bioorg Med Chem; 1995 Dec; 3(12):1651-6. PubMed ID: 8770389
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol depletion from the plasma membrane triggers ligand-independent activation of the epidermal growth factor receptor.
Chen X; Resh MD
J Biol Chem; 2002 Dec; 277(51):49631-7. PubMed ID: 12397069
[TBL] [Abstract][Full Text] [Related]
9. Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor.
Bhattacharya SK; Cox ED; Kath JC; Mathiowetz AM; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Richter DT; Su C; Wessel MD
Biochem Biophys Res Commun; 2003 Jul; 307(2):267-73. PubMed ID: 12859950
[TBL] [Abstract][Full Text] [Related]
10. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
[TBL] [Abstract][Full Text] [Related]
11. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
Kong A; Calleja V; Leboucher P; Harris A; Parker PJ; Larijani B
PLoS One; 2008 Aug; 3(8):e2881. PubMed ID: 18682844
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro.
Denny WA; Rewcastle GW; Bridges AJ; Fry DW; Kraker AJ
Clin Exp Pharmacol Physiol; 1996 May; 23(5):424-7. PubMed ID: 8713682
[TBL] [Abstract][Full Text] [Related]
13. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy.
Dowlati A; Nethery D; Kern JA
Mol Cancer Ther; 2004 Apr; 3(4):459-63. PubMed ID: 15078989
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.
Lu C; Mi LZ; Schürpf T; Walz T; Springer TA
J Biol Chem; 2012 Nov; 287(45):38244-53. PubMed ID: 22988250
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor.
Peace BE; Hill KJ; Degen SJ; Waltz SE
Exp Cell Res; 2003 Oct; 289(2):317-25. PubMed ID: 14499632
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
[TBL] [Abstract][Full Text] [Related]
19. Related adhesion focal tyrosine kinase and the epidermal growth factor receptor mediate the stimulation of mitogen-activated protein kinase by the G-protein-coupled P2Y2 receptor. Phorbol ester or [Ca2+]i elevation can substitute for receptor activation.
Soltoff SP
J Biol Chem; 1998 Sep; 273(36):23110-7. PubMed ID: 9722539
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
